SAB BIOTHERAPEUTICS, INC. Increase (Decrease) in Prepaid Expense
SAB BIOTHERAPEUTICS, INC. (SABS) reported Increase (Decrease) in Prepaid Expense of $523.61 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-29.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidExpense · last filed 2024-03-29
- SAB BIOTHERAPEUTICS, INC. increase (decrease) in prepaid expense for the quarter ending 2023-12-31 was $1.41M, a 155.56% increase year-over-year.
- SAB BIOTHERAPEUTICS, INC. increase (decrease) in prepaid expense for the quarter ending 2023-09-30 was -$230.56K.
- SAB BIOTHERAPEUTICS, INC. increase (decrease) in prepaid expense for the quarter ending 2023-06-30 was -$338.79K.
- SAB BIOTHERAPEUTICS, INC. increase (decrease) in prepaid expense for the quarter ending 2023-03-31 was -$318.90K, a 189.93% decline year-over-year.
- SAB BIOTHERAPEUTICS, INC. increase (decrease) in prepaid expense for fiscal 2023 was $523.61K.
- SAB BIOTHERAPEUTICS, INC. increase (decrease) in prepaid expense for fiscal 2022 was -$674.55K, a 153.61% decline from fiscal 2021.
- SAB BIOTHERAPEUTICS, INC. increase (decrease) in prepaid expense for fiscal 2021 was $1.26M, a 9.31% increase from fiscal 2020.
- SAB BIOTHERAPEUTICS, INC. increase (decrease) in prepaid expense for fiscal 2020 was $1.15M.
| Period end | Increase (Decrease) in Prepaid Expense 2 month | Increase (Decrease) in Prepaid Expense 3 month | Increase (Decrease) in Prepaid Expense 3 month as first filed | Increase (Decrease) in Prepaid Expense 6 month | Increase (Decrease) in Prepaid Expense 6 month as first filed | Increase (Decrease) in Prepaid Expense 9 month | Increase (Decrease) in Prepaid Expense 9 month as first filed | Increase (Decrease) in Prepaid Expense 12 month | Increase (Decrease) in Prepaid Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|
| 2023-12-31 | $1.41M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $1.18M derived: sum of 2 quarters · filed 2024-03-29 | $842.51K derived: sum of 3 quarters · filed 2024-03-29 | $523.61K 10-K · filed 2024-03-29 | |||||
| 2023-09-30 | -$230.56K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$569.35K derived: sum of 2 quarters · filed 2023-11-13 | -$888.25K 10-Q · filed 2023-11-13 | -$335.79K derived: sum of 4 quarters · filed 2024-03-29 | |||||
| 2023-06-30 | -$338.79K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-21 | -$657.69K 10-Q · filed 2023-08-21 | -$105.23K derived: sum of 3 quarters · filed 2024-03-29 | -$1.01M derived: sum of 4 quarters · filed 2024-03-29 | |||||
| 2023-03-31 | -$318.90K 10-Q · filed 2023-05-15 | $233.56K derived: sum of 2 quarters · filed 2024-03-29 | -$668.56K derived: sum of 3 quarters · filed 2024-03-29 | -$1.35M derived: sum of 4 quarters · filed 2024-03-29 | |||||
| 2022-12-31 | $552.46K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | -$349.66K derived: sum of 2 quarters · filed 2024-03-29 | -$1.03M derived: sum of 3 quarters · filed 2024-03-29 | -$674.55K 10-K · filed 2024-03-29 | |||||
| 2022-09-30 | -$902.12K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$1.58M derived: sum of 2 quarters · filed 2023-11-13 | -$1.23M 10-Q · filed 2023-11-13 | $544.74K 10-Q · filed 2022-11-14 | $362.90K derived: sum of 4 quarters · filed 2023-11-13 | ||||
| 2022-06-30 | -$679.50K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-21 | -$324.89K 10-Q · filed 2023-08-21 | $1.19M 10-Q · filed 2022-08-10 | $1.27M derived: sum of 3 quarters · filed 2023-08-21 | $1.78M derived: sum of 4 quarters · filed 2023-08-21 | ||||
| 2022-03-31 | $354.61K 10-Q · filed 2023-05-15 | $1.11M 10-Q · filed 2022-05-12 | $1.94M derived: sum of 2 quarters · filed 2023-05-15 | $2.46M derived: sum of 3 quarters · filed 2023-05-15 | $1.62M derived: sum of 4 quarters · filed 2023-05-15 | ||||
| 2021-12-31 | $1.59M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-04-28 | $2.11M derived: sum of 2 quarters · filed 2023-04-28 | $1.26M derived: sum of 3 quarters · filed 2023-04-28 | $1.26M 10-K/A · filed 2023-04-28 | -$513.36K 10-K · filed 2022-03-29 | ||||
| 2021-09-30 | $516.22K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$329.38K derived: sum of 2 quarters · filed 2022-11-14 | -$331.56K 10-Q · filed 2022-11-14 | ||||||
| 2021-06-30 | -$845.61K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | -$847.78K 10-Q · filed 2022-08-10 | $177.61K 10-Q · filed 2021-08-09 | ||||||
| 2021-03-31 | -$2.17K 10-Q · filed 2022-05-12 | $260.32K 10-Q · filed 2021-05-21 | |||||||
| 2020-12-31 | $2.56K 10-K · filed 2021-04-02 | $1.15M 10-K/A · filed 2023-04-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |